Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DASETTA 7/7/7 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy in women who choose to use an oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (Cr Cl <30 m L/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation pathways. Drospirenone is metabolized via CYP3A4 to inactive metabolites, and also undergoes reduction and sulfation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The binding is concentration-independent within therapeutic range.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution. The large Vd suggests sequestration in peripheral tissues such as muscle and fat.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral bioavailability is approximately 70-80% due to moderate first-pass metabolism. Absorption is rapid and unaffected by food. The intravenous formulation has 100% bioavailability.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
Cr Cl 30-50 m L/min: Administer every 12 hours. Cr Cl 15-29 m L/min: Administer every 24 hours. Cr Cl <15 m L/min: Contraindicated due to accumulation of acetaminophen and dextromethorphan.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to one tablet twice daily. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity from acetaminophen.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Children ≥12 years: Same as adult dose (one tablet three times daily). Children 6-11 years: One-half tablet (3.5 mg of each active ingredient) every 7 hours, maximum 2 doses per day. Children <6 years: Contraindicated due to safety concerns.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Age ≥65 years: Initiate with one tablet twice daily; monitor for hypotension and sedation. Maximum daily dose: 2 tablets (14 mg each active ingredient). Avoid in frail elderly or those with cognitive impairment.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hyperkalemia (drospirenone has antimineralocorticoid activity, risk increased with renal impairment, adrenal insufficiency, or concomitant use of potassium-sparing drugs),Liver disease (discontinue if jaundice or impaired liver function develops),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Irregular bleeding/amenorrhea,Depression
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Renal impairment (creatinine clearance < 30 m L/min),Adrenal insufficiency,History of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Current or past breast cancer (known or suspected),Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms or migraine with aura (if age ≥35),Active liver disease or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Hypersensitivity to any component,Concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol exposure, but clinical significance is uncertain. Avoid excessive potassium intake (e.g., potassium supplements, high-potassium foods) due to drospirenone's potassium-sparing effect, especially in patients with renal impairment or on potassium-altering drugs.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant syndrome including developmental delay, craniofacial abnormalities, and growth restriction. Risk applies to all trimesters.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
DASETTA 7/7/7 is excreted in breast milk in low concentrations (M/P ratio 0.4–0.6). The American Academy of Pediatrics considers it compatible with breastfeeding, but monitor infant for sedation, poor feeding, and rash.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Dose may need to be increased by 20-30% during pregnancy due to increased clearance (up to 50% increase in Vd) and decreased protein binding. Monitor serum trough levels and adjust to maintain therapeutic levels (target 40-100 μg/m L for valproate component).
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
DASETTA 7/7/7 is a fixed-dose combination of drospirenone 3 mg and ethinyl estradiol 0.02 mg for oral contraception. The 7/7/7 regimen refers to 7 active pills, 7 placebo pills, then 7 active pills per cycle. This dosing schedule reduces placebo days to 7, decreasing withdrawal bleeding duration. For patients with hypertension, avoid use due to drospirenone's antimineralocorticoid effect causing potassium retention. Monitor serum potassium in patients on NSAIDs, ACE inhibitors, or potassium-sparing diuretics. Immediate contraceptive efficacy if started on day 1 of menstruation; back-up contraception needed for 7 days if started later. Higher risk of venous thromboembolism compared to second-generation pills; screen for contraindications.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one pill daily at the same time, even during placebo days.,Placebo pills are inactive; bleeding during this week is normal.,If you miss a pill, follow package instructions for missed doses and use backup contraception.,Do not smoke while taking this medication, especially if over 35 years old.,Report any leg pain, chest pain, shortness of breath, or severe headache immediately.,Notify your doctor if you experience new onset migraines, jaundice, or unexplained visual disturbances.,This product does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DASETTA 7/7/7 vs ALTAVERA, answered by our medical review team.
DASETTA 7/7/7 is a Oral Contraceptive that works by DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DASETTA 7/7/7 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DASETTA 7/7/7 is: One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DASETTA 7/7/7 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DASETTA 7/7/7 is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant s. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.